

# Ocrelizumab for Psychosis by Autoimmunity

NCT03971487

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1, Phase 2
<b>Sponsor</b>	The Methodist Hospital Research Institute
<b>Enrollment</b>	40 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Individuals of either sex, 18-35 years of age.
- Having an active psychotic disorder meeting DSM-5 criteria, including a duration of at least six months, for Schizophrenia Spectrum Disorder, as defined by the Mini International Neuropsychiatric Interview (MINI).
- A total PANSS  $\leq 60$  and a score  $\leq 4$  on at least 2 of the PANSS positive symptoms.
- Normal academic performance at least until the age of 15 years and absence of psychiatric symptoms before the same age.
- Ability to assent or consent to the performance of the study and participate in testing procedures.

### Exclusion (12)

- The dose of antipsychotic medication (if they are on one) has been changed less than two weeks prior to baseline PANSS testing (Visit 2, see below).
- Patient treated with a medication designed to suppress the immune system, other than standard analgesics or antipyretics, in the six months prior to randomization.
- Vaccinated with a live-attenuated vaccine less than 4 weeks before ocrelizumab infusion or with a non-live vaccine less than 2 weeks before infusion.
- Active infection, or history of or known presence of recurrent or chronic infection (for example, hepatitis B or C, Human Immunodeficiency Virus, syphilis, tuberculosis, PML).
- History of brain tumor, stroke, severe head trauma or multiple sclerosis.
- ... and 7 more (see full listing online)

## Locations (1 total)

---

Houston Methodist Research Institute, Houston, Texas, United States